Dabigatran Enteric Pellets pH-Independent Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of dabigatran etexilate suffer from pH-dependent dissolution, low absorption in the stomach, and instability, leading to dose-dumping and reduced shelf-life.
Innovation Solution
A novel enteric coated pellet formulation using dabigatran etexilate free base with methacrylic acid-ethyl acrylate copolymer and fumaric acid as key components, which enhances solubility and stability, and includes polyvinylpyrrolidone as a binder to ensure pH-independent release and improved absorption in the small intestine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If dabigatran etexilate is formulated as acid addition salts (methanesulfonate, oxalate, hydrochloride), then the compound can be prepared to facilitate pharmaceutical formulation development, but the formulations exhibit pH-dependent dissolution and instability leading to dose-dumping and reduced shelf-life
Solution Approach 1:
The patent changes the chemical form of dabigatran etexilate from acid addition salts to the free base form. This parameter change fundamentally alters the dissolution behavior, enabling pH-independent release while improving stability and preventing dose-dumping, thus resolving the contradiction between ease of formulation development and reliability of shelf-life
Solution Approach 2:
The patent creates a composite formulation combining dabigatran etexilate free base with specific excipients and coating materials (enteric coating). This composite approach enables the formulation to achieve both manufacturability and enhanced stability with pH-independent dissolution, overcoming the limitations of salt forms
2Quantity of substance
If dabigatran etexilate is dissolved in acidic media (stomach), then the compound can be absorbed, but absorption is negligibly low due to fast peristaltic movements and high surface area of the stomach
Solution Approach 1:
The patent applies enteric coating to the pellets before administration. This preliminary action protects the drug from immediate dissolution in the stomach and directs dissolution to occur in the small intestine, where slower peristaltic movements and appropriate pH conditions facilitate effective absorption
Solution Approach 2:
The enteric coating acts as an intermediary layer between the dabigatran etexilate free base and the gastric environment. It controls the release timing and location, allowing the drug to reach the small intestine where absorption occurs effectively, thus overcoming the rapid peristalsis limitation of the stomach
3Reliability
If dabigatran etexilate is formulated with enteric coating and specific excipients, then pH-independent release and improved absorption are achieved, but the formulation complexity increases
Solution Approach 1:
The patent changes the core parameter of using free base form instead of salts, which simplifies the overall formulation strategy. This parameter change enables pH-independent release and eliminates the need for complex buffering systems, reducing formulation complexity while achieving reliable pH-independent release
Solution Approach 2:
The dabigatran etexilate free base formulation utilizes the inherent properties of the free base form and enteric coating to achieve pH-independent release. The system is designed to be self-regulating, where the coating naturally directs dissolution to the appropriate location without requiring additional complex control mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves stable, pH-independent drug release, increased absorption, and enhanced stability and shelf-life, minimizing dose-dumping and gastrointestinal irritation.
Implementation Method 1
a novel enteric coated pellet formulation using dabigatran etexilate free base with methacrylic acid-ethyl acrylate copolymer
Implementation Method 2
fumaric acid as key components, which enhances solubility and stability
Implementation Method 3
includes polyvinylpyrrolidone as a binder to ensure pH-independent release and improved absorption
Data Source
AI summary
The present invention relates to a novel pharmaceutical enteric coated pellet formulations comprising dabigatran etexilate free base as an active agent and at least one pharmaceutically acceptable excipient. The present invention further relates to a highly soluble and stable formulations comprising dabigatran etexilate free base as an active agent.